We tested the hypothesis that administration of the antioxidant tirilazad mesylate improves electrophysiological recovery and decreases infarct volume after transient focal cerebral ischemia in cats.
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Background and Purpose We tested the hypothesis that administration of the antioxidant tirilazad mesylate improves electrophysiological recovery and decreases infarct volume after transient focal cerebral ischemia in cats.
Methods Halothane-anesthetized cats underwent 90 minutes of left middle cerebral artery and bilateral common carotid artery occlusion followed by 180 minutes of reperfusion. Cats were assigned to receive tirilazad (1.5 mg/kg plus 0.2 mg/kg per hour IV infusion) either at the beginning (n=9) or conclusion (n=9) of ischemia. Control cats received an equal volume of diluent (citrate buffer, pH 3.0; n=7) at the beginning and conclusion of ischemia in a blinded fashion. Infarct volume was measured by 2,3,5-triphenyltetrazolium chloride staining.
Results Blood flow to the left temporoparietal cortex decreased to less than 10 mL/min per 100 g with ischemia but was minimally affected on the right side. Blood flow distribution during ischemia or reperfusion was not different in the tirilazad-treated groups. No group demonstrated postischemic L ipid peroxidation, resulting from increased production of oxygen radicals, has been implicated as an important pathway for production of brain injury during ischemia and subsequent reperfusion. 1 During middle cerebral artery (MCA) occlusion there is gradation of blood flow reduction. 2 In the regions with the most intense ischemia, blood flow normally remains constant at a low value during 2 hours of MCA occlusion. On the contrary, blood flow increases in the regions of greatest ischemia during MCA occlusion in animals pretreated with the oxygen radical scavenger superoxide dismutase. 3 Treatment with superoxide dismutase before MCA occlusion is also associated with attenuated brain injury in animals allowed to experience either full 3 or partial 4 -5 reperfusion.
Tirilazad mesylate (21-[4-(2,6-di-l-pyrrolidinyl-4-pyrimidinyl)-l-piperazinyl]-16a-methylpregna-l,4,9(ll)-triene-3,20-dione, monomethane sulfonate) is a potent inhibitor of both iron-dependent and iron-independent lipid peroxidation in vitro. 5 - 7 Lipid peroxidation has been demonstrated in some models of transient global ischemia 8 changes in concentration of endogenous antioxidants are consistent with lipid peroxidation in the region of ischemia, and these changes are attenuated by tirilazad treatment. 11 One potential mechanism for production of oxygen radicals in cats exposed to transient focal ischemia is through metabolism of arachidonate via the cyclooxygenase pathway. 12 Because tirilazad has been demonstrated to inhibit arachidonic acid-induced breakdown of the blood-brain barrier, 13 we anticipated a therapeutic effect in our model of transient focal ischemia. The goal of this study was to test whether the antioxidant tirilazad would prevent acute neuronal injury in a model of severe focal ischemia and full reperfusion that we have previously demonstrated to be partially dependent on an oxygen radical mechanism. 
Materials and Methods
Female cats (weight, 23 to 4.1 kg) were anesthetized with halothane in oxygen during spontaneous ventilation. After induction of anesthesia cats were orally intubated and mechanically ventilated to maintain Paco^ at approximately 35 to 40 mm Hg. Anesthesia was maintained with halothane (0.5% to 1.5%) in oxygen-enriched air. Halothane concentration was increased for signs of cardiovascular stimulation during surgery but was not changed throughout the experimental protocol.
Catheters were placed in both femoral veins for infusion of fluids (lactated Ringer's solution) and drugs and in the descending aorta via a femoral artery for blood pressure record-ing, arterial blood gas sampling, and withdrawal of reference blood samples during injection of radiolabeled microspheres. A catheter placed in the left atrium via a left thoracotomy was used for injection of radiolabeled microspheres. Moistened ligatures were loosely applied to both common carotid arteries for later occlusion.
The cat was turned prone and its head positioned in a stereotaxic frame approximately 4 cm higher than its heart. A thermistor placed in the right temporal epidural space acted as an estimate of brain temperature. Epidural temperature was maintained at 38.0±0.5°C using a heating pad and a heating lamp throughout the protocol. The left MCA was exposed by a transorbital approach using microsurgical techniques.
-
14 To produce focal ischemia, the MCA was reversibry occluded near its origin using a microvascular clip, and both common carotid arteries were reversibly occluded by tightening previously placed ligatures.
Arterial blood pressure was recorded continuously. Arterial pH, PCO2, and P02 were measured with a self-calibrating Radiometer electrode system (ABL 3) corrected for the cat's brain temperature. Hemoglobin and arterial O 2 content were measured with a CO-Oximeter (Instrumentation Laboratory model 282). Blood glucose was measured with a glucose analyzer (YSI model 23A). Somatosensory evoked potentials (SEP) were measured using a multichannel signal averager (Nicolet CA-1000, Nicolet Instruments Corp) as previously described. 15 The amplitude of the first negative wave occurring at approximately 12 to 14 milliseconds was measured and recorded. Regional cerebral blood flow (CBF) was measured with radiolabeled microspheres (16±0.5 /xm in diameter; Dupont-NEN Products) using the reference withdrawal method. 1 Sc) were injected in random sequence in each animal. Approximately 1.5x10' to 2x10' microspheres were injected into the left atrium over a 20-second period followed by a 5-mL saline flush. The reference blood sample was withdrawn from the aorta at 1.94 mL/min beginning 30 seconds before the injection and continuing for 90 seconds after the saline flush.
At the end of the experiment the animal was killed with KC1. The brain was removed, and coronal sections 2.5 mm thick were cut immediately. The slices were then incubated in a 1% solution of 2,3,5-triphenyltetrazolium chloride (TTC) for 40 minutes at 37°C. Regions that failed to demonstrate dark red staining with TTC were considered to represent areas of brain infarction.
17
- 19 Each slice was photographed in color, and the area of infarction was determined on both surfaces of 12 sections by digital planimetry. Infarct volume was calculated by averaging the anterior and posterior injury area of each slice, multiplying by section thickness, and summing these volumes over the entire hemisphere. Caudate infarct volume was calculated separately. The slices of brain were placed in 10% buffered formalin for 1 to 2 days. Ipsilateral and contralateral temporal and parietal lobe slices were sectioned subsequently into three cortical gray matter regions (temporal, temporoparietal, and parietal). Brain was also sectioned to determine regional CBF as previously described.
Three groups of cats were studied in a randomized and blinded fashion to evaluate the effect of treatment with tirilazad before and at the end of 90 minutes of ischemia. Investigators remained blinded to treatment group until data were completely analyzed from all cats in the study. In the control group (n=7), just after tightening the ligatures around the common carotid arteries, 1 mL/kg of vehicle (0.02 mol/L citric acid monohydrate, 0.0032 mol/L sodium citrate dihydrate, 0.077 mol/L NaCl, pH 3.0) was administered over 12 to 15 minutes and then by continuous intravenous infusion at 0.375 mL/h for the duration of the experiment. At 70 minutes of ischemia a second infusion of 1 mL/kg of vehicle was administered over 12 to 15 minutes and then by continuous intravenous infusion at 0.375 mL/h for the duration of the experiment.
In the pretreatment group (n=9), just after tightening the ligatures around the common carotid arteries, 1.5 mg/kg (1.5 mg/mL) of tirilazad was administered over 12 to 15 minutes by continuous intravenous infusion at 0.375 mL/h (approximately 0.2 mg/kg per hour) for the duration of the experiment. At 70 minutes of ischemia infusion of 1 mL/kg of vehicle was administered over 12 to 15 minutes by continuous intravenous infusion at 0.375 mL/h for the duration of the experiment.
In the posttreatment group (n=9), just after tightening the ligatures around the common carotid arteries, 1 mL/kg of vehicle was administered over 12 to 15 minutes by continuous intravenous infusion at approximately 0.375 mL/h for the duration of the experiment. At 70 minutes of ischemia infusion of 1.5 mg/kg of tirilazad was administered over 12 to 15 minutes by continuous intravenous infusion at 0.375 mL/h for the duration of the experiment.
In all groups the microvascular clip was placed on the left MCA, and SEP were recorded to document a decrease in amplitude of the major cortical negative wave to less than 25% of preischemic value; then the ligatures around the common carotid arteries were tightened. If SEP amplitude did not decrease below 25% of preischemic value by 5 minutes of occlusion (before administration of drug or diluent) the animal was excluded from further analysis. Evoked potentials were measured before ischemia and at 5,15, 30, 60, and 90 minutes of ischemia. After 90 minutes of ischemia the carotid ligatures were loosened, and the microvascular clip on the MCA was removed. Reperfusion lasted 180 minutes. SEP were measured at 15, 30, 60, 90, 120, 150, and 180 minutes of reperfusion. Arterial blood gas and CBF measurements were made before ischemia, at 20 and 85 minutes of ischemia, and at 60,120, and 180 minutes of reperfusion.
Values are expressed as mean±SE. Analysis between groups for physiological variables, blood flow, SEP amplitude, and infarct volumes were made with one-way ANOVA. Within-group comparisons were made with the paired / test using a Bonferroni correction. Statistical significance was set at Ps.05. Table 1 demonstrates physiological variables for each group of cats. Before ischemia (before drug or vehicle treatment) hemoglobin concentration was greater in both experimental groups, and blood glucose concentration tended to be highest in the control group (P=.07). However, there were no physiologically significant differences between groups for blood gas data, mean arterial blood pressure (MABP), or glucose during ischemia or reperfusion.
Results
During left MCA and bilateral common carotid artery occlusion, the most profound decrease in blood flow occurred in ipsilateral temporoparietal cortex and in caudate nucleus (Table 2) . No group demonstrated consistent postischemic hyperemia at 60 minutes of reperfusion or delayed hypoperfusion. There was also no difference between either experimental group and the control group for blood flow at any time point. However, within each group there were several cats that did demonstrate postischemic hyperemia at 60 minutes of reperfusion (eg, ipsilateral temporal region: control, 4 of 7 cats; pretreatment, 7 of 9 cats; posttreatment, 6 of 9 cats) and delayed hypoperfusion at 180 minutes of reperfusion (eg, ipsilateral temporal region: control, 4 of 7 cats; pretreatment, 5 of 9 cats; posttreatment, 6 of 9 cats). Regardless of group, all cats that did not demonstrate postischemic hyperemia did demonstrate severe delayed hypoperfusion (eg, ipsilateral temporal region at 180 minutes of reperfusion, 7.0±2.8% of baseline, n=8). Values are mean±SE. MABP Indicates mean arterial blood pressure; Hb, hemoglobin concentration. Control group before Ischemia (n~7), diluent at onset of Ischemia and reperfuslon; pretreatment group (n-9), tirilazad at onset of Ischemia, diluent at reperfuslon; posttreatment group (n=9), diluent at onset of Ischemia, tirilazad at reperfuslon. *Ps.O5 vs control group.
Blood flow to hippocampus and posterior fossa was not affected by vascular occlusion. Blood flow to right-sided (contralateral) brain regions was not affected by left MCA and bilateral carotid artery occlusion (Table 2) .
Baseline SEP amplitude was similar between groups and not different for ipsilateral (control, 75 ±11 /iV; pretreatment, 74±8 ixV; posttreatment, 81±12 fj.V) and contralateral cortex (control, 74±13 fiV; pretreatment, 61 ±11 AIV; posttreatment, 80±10 jtV). During ischemia, SEP amplitude over the left somatosensory cortex was suppressed to 0% to 5% of preischemic values in all groups. At 180 minutes of reperfusion, return of SEP amplitude was minimal (control, 8±4%; pretreatment, 8 ±4%, posttreatment, 10 ±6%), and there were no differences between groups. All cats had normal latency of the wave measured over the second cervical vertebrae. Contralateral SEP amplitude was not different from baseline by 180 minutes of reperfusion in control cats (95 ±19% of baseline at 180 minutes). At 180 minutes of reperfusion contralateral SEP amplitude was 38±14% of baseline in pretreatment cats and 50±19% of baseline in posttreatment cats; however, there was no difference between treatment groups and the control group.
There were no differences among groups in the volume of infarcted left hemisphere (control, 1936±508 mm (Figure) . Furthermore, there were no differences in hemispheric infarct volume when expressed as a percentage of left hemisphere volume (control, 28±8%; pretreatment, 25±6%; posttreatment, 33±5%) or in caudate infarct volume expressed as a percentage of left caudate volume (control, 55 ± 13%; pretreatment, 46±7%; posttreatment, 41 ±10%). Because the infarct volume may be altered by edema, we also compared the remaining noninfarcted ipsilateral volumes, which should not be greatly influenced by edema. There were no differences among groups in the volume of ipsilateral noninfarcted hemisphere (control, 5530±485 mm 
79±14
Values are mean±SE, expressed In mllllltters per minute per 100 g. Control group (n=7), diluent at onset of ischemia and reperfuslon; pretreatment group (n-9), tirilazad at onset of ischemia, diluent at reperfuslon; posttreatment group (n=9), diluent at onset of Ischemia, tirilazad at reperfusion. *Ps.O5 vs baseline value. There was no difference for any variable compared with control group at any time.
caudate nucleus (control, 114 ±27 mm 3 ; pretreatment, 120±ll mm 3 ; posttreatment, 107±20 mm 3 ) after transient focal ischemia. No animal in either group demonstrated injury in the right hemisphere or right caudate nucleus. Discussion Cats exposed to 90 minutes of MCA and bilateral common carotid artery ligation followed by 180 minutes of reperfusion were found to have poor recovery of SEP amplitude and large volumes of neuronal injury in the left hemisphere and caudate nucleus. Administration of tirilazad did not alter the distribution of blood flow reduction to regions ipsilateral or contralateral to MCA occlusion. No group was found to have consistent postischemic hyperemia or delayed hypoperfusion. There was also no difference between groups for recovery of SEP amplitude or volume of neuronal injury measured in the left hemisphere or caudate nucleus. Our data, therefore, do not support the hypothesis that the antioxidant tirilazad (at a dose of 1.5 mg/kg bolus and 0.2 mg/kg per hour IV infusion) results in decreased size of the injury or improved electrophysiological function after severe transient focal cerebral isch- Ipsllateral to left middle cerebral plus bilateral carotid artery occlusion In animals treated with diluent before Ischemia and at end of Ischemia (CONTROL), animals treated with tirllazad before ischemia and diluent at end of Ischemia (PRETREAT), and animals treated with diluent before Ischemia and tirllazad at end of ischemia (POSTTREAT). There were no differences between groups at any time.
emia in cats whether administered at the onset of ischemia or reperfusion.
Several previous studies have demonstrated a role of oxygen radicals in the pathophysiology of brain injury from transient 3 and prolonged 4 -5 focal ischemia. Oxygen radicals can cause brain injury by direct attack on vascular structures 20 or by attacking the molecular structure of the cell. 21 In the presence of ferrous iron, superoxide anion may participate in Fenton chemistry with production of the very reactive hydroxyl radical, which then participates in the process of lipid peroxidation. Although lipid peroxidation has been found to occur after transient ischemia, 8 ' 1011 the peak effects may not occur for several hours after reperfusion. Tirilazad is a potent inhibitor of lipid peroxidation and therefore is presumed to protect brain exposed to ischemia and reperfusion via this mechanism. 6 -7 The observation that tirilazad attenuates ischemic-induced depletion of vitamin E and head injury-induced generation of hydroxyl radicals in vivo 22 supports this mechanism of action. However, tirilazad also attenuates excitotoxic neuronal injury in cortical cell cultures. 23 To maximize the potential for therapeutic efficacy for tirilazad in this model, in the pretreatment group drug was administered as a continuous infusion throughout ischemia and reperfusion.
The literature on efficacy of tirilazad in inhibiting brain injury after ischemia and reperfusion is mixed. Differences in efficacy between studies may be due to one of many different issues, such as differences in the model of ischemia, in species, in baseline anesthetic, in dose used or timing of administration, and in outcome measures that are reported. In regard to the model used, tirilazad improves neurological recovery after transient complete global ischemia 24 but does not improve early recovery of CBF, cerebral oxygen consumption, SEP, or high-energy phosphates 23 and is not associated with decreased neurological injury. 26 In contrast, after incomplete global ischemia tirilazad improves rate of recovery of high-energy phosphates 27 -28 and attenuates damage in neocortex 29 but does not improve neurological outcome. 30 In studies of transient focal ischemia tirilazad reduces neuronal injury in rats, 31 but in our cat model there was no attenuation of infarct volume or improvement in SEP recovery. However, infarct volume was measured at 180 minutes of reperfusion in our study. At 180 minutes of reperfusion TTC staining appears to closely estimate the degree of histological injury. 32 However, because delayed neuronal necrosis occurring over several days acts to extend the infarction, we cannot exclude that tirilazad administration during a more prolonged recovery period would be beneficial.
It is possible that the lack of effect of tirilazad administered at the start or end of transient focal cerebral ischemia is related to dose or route of administration. However, the intravenous dose of tirilazad used in this study was similar to an intravenous dose (1 mg/kg bolus and 0.2 mg/kg per minute infusion) found to improve rate of recovery of high-energy phosphates after severe incomplete ischemia 28 and to improve neurological outcome in dogs exposed to transient complete ischemia (two 1.5 mg/kg IV boluses separated by 26 minutes). 24 Nevertheless, we administered the initial dose of tirilazad after the start of ischemia or before reperfusion, rather than before ischemia, to mimic the clinical setting. It is possible that the low CBF during ischemia may have limited delivery of drug to the densely ischemic region.
In our laboratory efficacy of tirilazad in improving early metabolic recovery from global ischemia is most marked when tissue pH falls below e^. 34 Other studies suggest that 4 hours of MCA occlusion may be required to reduce tissue pH to 6.2. 35 ' 36 Therefore, one potential reason for the lack of therapeutic benefit for tirilazad during 90 minutes of transient focal ischemia may be due to a limited amount of intracellular acidosis.
We measured blood flow at two points during ischemia to determine if tirilazad altered blood flow distribution during MCA occlusion. We previously found that administration of superoxide dismutase, using a similar experimental paradigm, resulted in a gradual increase in flow in the ischemic region and diminished caudate infarct volume. 3 In tirilazad-treated cats there was no change in blood flow during ischemia, nor was there an effect on infarct volume. In this model with concurrent bilateral carotid occlusion, the reduction of CBF was severe (less than 10 mL/min per 100 g) within a considerable portion of cortex. It is possible that 90 minutes of severely dense ischemia may be too great of an insult to yield substantial effect by tirilazad on infarct volume. We also found no evidence of postischemic hyperemia. It is possible that postischemic hyperemia was not detected because the first blood flow measurement during reperfusion was not until 60 minutes. However, we have previously measured CBF as early as 15 minutes of reperfusion and demonstrated postischemic hyperemia after transient focal ischemia in cats anesthetized with pentobarbital or a-chloralose but not with halothane or fentanyl. 37 By chance hemoglobin concentration was lower in control cats compared with the other two groups at baseline conditions (Table 1) . Because moderate he-modilution can attenuate infarct volume, 38 it is possible that infarct volume in the control group was lower than normal because of hemodilution and thereby masked a beneficial effect of tirilazad. However, blood flow was not higher during ischemia in the control group, as would be anticipated. In addition, infarct volumes in control animals were similar to previously published control values using this model. 15 It is also possible that higher hemoglobin in the tirilazad groups would result in more iron available to induce lipid peroxidation. 39 However, we believe that this is of questionable importance because (1) there were no differences between groups in hemoglobin concentration during reperfusion, which is the time oxygen radicals are produced as a result of ischemia in cats, 40 (2) it is unlikely that minor differences in red cell-based hemoglobin would have a significant impact on the amount of hemolysate at the injury site, and (3) free hemoglobin transfusion does not exacerbate ischemic injury. 41 Blood glucose tended to be higher in the control gToup compared with the drug-treated groups. Hyperglycemia has been associated with impaired neurological recovery after transient global ischemia. 42 - 43 However, because hypergh/cemia has been demonstrated to either ameliorate 44 or worsen 45 neurological injury in the setting of focal ischemia, the effect of a tendency for elevated preischemic glucose levels in drug-treated animals cannot be predicted.
Another consideration is sex. Hall et al 46 observed less postischemic neuronal loss associated with less depletion of vitamin E in female gerbils compared with male gerbils. They attributed these sex differences to the antioxidant effects of 17-/3-estradiol, which they found was more potent in inhibiting lipid peroxidation in brain homogenates than vitamin E. Our study was conducted in female cats. Thus, it is possible that estradiols mitigated potential therapeutic effects of tirilazad.
In conclusion, we found that treatment with tirilazad at the beginning or end of transient combined left MCA and bilateral common carotid artery occlusion in cats does not ameliorate brain injury as measured by TTC staining or SEP amplitude. Our data cannot exclude the possibility that a higher dose or different, timing of administration may be beneficial in a less severe model of focal ischemia or with a longer recovery period.
